Chuck Royce's CTKB Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 1.64 M shares of Cytek Biosciences, Inc. (CTKB) worth $7.18 M, representing 0.07% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 13 quarters.
Based on 13F filings, Chuck Royce has maintained a strategic position in CTKB, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 823,987 shares. Largest reduction occurred in Q4 2023, reducing 87,489 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Cytek Biosciences (CTKB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cytek Biosciences (CTKB) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -50,289 | Reduce 2.97% | 1.64 M | $4.37 |
| Q4 2025 | -70,605 | Reduce 4.00% | 1.69 M | $5.05 |
| Q3 2025 | +373,456 | Add 26.87% | 1.76 M | $3.47 |
| Q2 2025 | +823,987 | Add 145.63% | 1.39 M | $3.40 |
| Q1 2025 | +95,000 | Add 20.18% | 565,819 | $4.01 |
| Q4 2024 | +289,425 | Add 159.56% | 470,819 | $6.49 |
| Q3 2024 | +61,916 | Add 51.82% | 181,394 | $5.54 |
| Q2 2024 | +108,128 | Add 952.67% | 119,478 | $5.58 |
| Q1 2024 | +11,350 | New Buy | 11,350 | $6.71 |
| Q4 2023 | -87,489 | Sold Out | 0 | $0.00 |
| Q3 2023 | +15,209 | Add 21.04% | 87,489 | $5.52 |
| Q2 2023 | +27,866 | Add 62.74% | 72,280 | $8.54 |
| Q1 2023 | +44,414 | New Buy | 44,414 | $9.19 |
Chuck Royce's Cytek Biosciences Investment FAQs
Chuck Royce first purchased Cytek Biosciences, Inc. (CTKB) in Q1 2023, acquiring 44,414 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Cytek Biosciences, Inc. (CTKB) for 13 quarters since Q1 2023.
Chuck Royce's largest addition to Cytek Biosciences, Inc. (CTKB) was in Q2 2025, adding 1,389,806 shares worth $4.73 M.
According to the latest 13F filing for Q1 2026, Chuck Royce's firm, Royce & Associates Lp, owns 1,642,368 shares of Cytek Biosciences, Inc. (CTKB), valued at approximately $7.18 M.
As of the Q1 2026 filing, Cytek Biosciences, Inc. (CTKB) represents approximately 0.07% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in Cytek Biosciences, Inc. (CTKB) was 1,763,262 shares, as reported at the end of Q3 2025.